Cargando…
PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429899/ http://dx.doi.org/10.1097/01.HS9.0000974880.20066.a9 |
| _version_ | 1785090826289807360 |
|---|---|
| author | Garcia-Manero, Guillermo Matsuno, Rayna K. Mcbride, Ali Makinde, Adeola Y Brown, Thomas D. Idryo, Danny Broome, Ronda Herriman, Autumn Wilkinson, Kristiana Walters, Sheetal Schrag, Andrew Mohammed, Hina Izano, Monika A. Mukherjee, Sudipto |
| author_facet | Garcia-Manero, Guillermo Matsuno, Rayna K. Mcbride, Ali Makinde, Adeola Y Brown, Thomas D. Idryo, Danny Broome, Ronda Herriman, Autumn Wilkinson, Kristiana Walters, Sheetal Schrag, Andrew Mohammed, Hina Izano, Monika A. Mukherjee, Sudipto |
| author_sort | Garcia-Manero, Guillermo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429899 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104298992023-08-17 PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS Garcia-Manero, Guillermo Matsuno, Rayna K. Mcbride, Ali Makinde, Adeola Y Brown, Thomas D. Idryo, Danny Broome, Ronda Herriman, Autumn Wilkinson, Kristiana Walters, Sheetal Schrag, Andrew Mohammed, Hina Izano, Monika A. Mukherjee, Sudipto Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429899/ http://dx.doi.org/10.1097/01.HS9.0000974880.20066.a9 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Garcia-Manero, Guillermo Matsuno, Rayna K. Mcbride, Ali Makinde, Adeola Y Brown, Thomas D. Idryo, Danny Broome, Ronda Herriman, Autumn Wilkinson, Kristiana Walters, Sheetal Schrag, Andrew Mohammed, Hina Izano, Monika A. Mukherjee, Sudipto PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS |
| title | PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS |
| title_full | PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS |
| title_fullStr | PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS |
| title_full_unstemmed | PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS |
| title_short | PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS |
| title_sort | pb2017: clinical outcomes by sf3b1 mutation status in patients with lower-risk myelodysplastic syndromes retreated with erythropoiesis-stimulating agents |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429899/ http://dx.doi.org/10.1097/01.HS9.0000974880.20066.a9 |
| work_keys_str_mv | AT garciamaneroguillermo pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT matsunoraynak pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT mcbrideali pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT makindeadeolay pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT brownthomasd pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT idryodanny pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT broomeronda pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT herrimanautumn pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT wilkinsonkristiana pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT walterssheetal pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT schragandrew pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT mohammedhina pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT izanomonikaa pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents AT mukherjeesudipto pb2017clinicaloutcomesbysf3b1mutationstatusinpatientswithlowerriskmyelodysplasticsyndromesretreatedwitherythropoiesisstimulatingagents |